The high cost of cancer drugs and what we can do about it

Mayo Clinic Proceedings

Volumn 88, Issue 3, 2013, Pages 306-

  Rosamond, Thomas ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

DECISION MAKING; DRUG COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROGRAM; HEALTH STATUS; HUMAN; LETTER; MALIGNANT NEOPLASTIC DISEASE; QUALITY OF LIFE; RESOURCE ALLOCATION; UNITED KINGDOM; VISUAL ANALOG SCALE;

EID: 84876550337     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.01.003     Document Type: Letter

References (5)

1. Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87(10):935-943.
2. Richardson J, Hall J, Salkeld. The measurement of utility in multiphase health states. Int J Technol Assess Health Care. 1996;12(1):151-162. (Pubitemid 26098463)
3. Drummond MF, Sculpher MW, Torrance GW, Obrien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, England: Oxford University Press; 2005.
4. Robinson R. Economic evaluation in healthcare: cost utility analysis. BMJ. 1993;307:859-862.
5. Nord E, Richardson J, Macarounas-Kirchmann K. Social evaluation of health care versus personal evaluation of health states: evidence on the validity of four health-state scaling instruments using Norwegian and Australian survey. Int J Technol Assess Health Care. 1993;9(4):463-478. (Pubitemid 23348733)